Literature DB >> 33385837

Synthesis and evaluation of a collection of purine-like C-nucleosides as antikinetoplastid agents.

Jakob Bouton1, Louis Maes2, Izet Karalic1, Guy Caljon3, Serge Van Calenbergh4.   

Abstract

The kinetoplastid parasites Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp. are the causative agents of neglected tropical diseases with a serious burden in several parts of the world. These parasites are incapable of synthesizing purines de novo, and therefore rely on ingenious purine salvage pathways to acquire and process purines from their host. Purine nucleoside analogs that may interfere with these pathways therefore constitute a privileged source of new antikinetoplastid agents. In this study, we synthetized a collection of C-nucleosides employing five different heterocyclic nucleobase surrogates. C-nucleosides are chemically and enzymatically stable and allow for extensive structural modification. Inspired by earlier 7-deazaadenosine nucleosides and known antileishmanial C-nucleosides, we introduced different modifications tailored towards antikinetoplastid activity. Both adenosine and inosine analogs were synthesized with the aim of discovering new antikinetoplastid hits and expanding knowledge of structure-activity relationships. Several promising hits with potent activity against Trypanosoma brucei, Trypanosoma cruzi and Leishmania infantum were discovered, and the nature of the nucleobase surrogate was found to have a profound influence on the selectivity profile of the compounds.
Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antiparasitic; C-nucleosides; Leishmania; Trypanosoma

Mesh:

Substances:

Year:  2020        PMID: 33385837     DOI: 10.1016/j.ejmech.2020.113101

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  1 in total

1.  Acyclic nucleoside phosphonates with adenine nucleobase inhibit Trypanosoma brucei adenine phosphoribosyltransferase in vitro.

Authors:  Eva Doleželová; Tomáš Klejch; Petr Špaček; Martina Slapničková; Luke Guddat; Dana Hocková; Alena Zíková
Journal:  Sci Rep       Date:  2021-06-25       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.